Odyssey Therapeutics (ODTX) logo

Odyssey Therapeutics (ODTX) stock

Worth $961MShares as of Nov 2

$20.00
+4.44%

As of Tuesday's close · Live for Pro members at the open

Not scored

Breakaway doesn't score ODTX. It is too thinly traded for a fair Quality Score.

Healthcare · Biotech

NextEnd of 2026“…to selectively modulate pathogenic B cell populations to treat autoimmune disease, by the end of this year…”Filing with regulators · SEC filing · Aug 4

Follow ODTX's trial news. Pro members can get an alert when Odyssey Therapeutics files news, and see its trials, share raises, and its CEO's filings.

Get an alert when ODTX files news on its trialsSee it live, free until Thursday morning. No account. No card. Then keep going with a free account.

We do the work for you. 3,168 stocks are scored and ranked, every 15 seconds while the market is open. Pro members see it live.

What's next for ODTX, and how long its cash lasts

Next step the company has named

End of 2026“…CTA for our second clinical program, OD-002, an oral SLC15A4 inhibitor designed to selectively modulate pathogenic B cell populations to treat autoimmune disease, by the end of this year.”Filing with regulators · SEC filing · Aug 4

What it means: a filing asks regulators to approve a drug for sale. Once it is complete and accepted, the FDA sets a decision date, and we show it here.

Lead program
OD-002
Another trial
Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]OD-001 in Healthy Male ParticipantsPhase 1 · Recruiting · 8 people · main data estimated Dec 2026 · NCT07900607

1 more trial, 6 more milestones and 7 filings, for Pro members.

Cash runway Sep 30 balance sheet

$387M in cash

Fewer than four quarters of cash flow are on file.

What it means: a runway is counted only when each of the last four quarters used cash. The company's estimate is “into the second half of 2028” (8-K, Nov 4).

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

No shelf registration or at-the-market program on file in the last three years.

For Pro members: 1 raise and its amount, and the share count against a year ago.

Insiders

Director Nan (ln) Li bought 1,111,111 shares on May 11. 4 more insider trades this year.

From Form 4: open-market buys and sales only.

For Pro members: every trade, and Gary Glick’s 2 filings and quotes.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

14 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 151 dates, ranked →

ODTX's latest filings

13 more filings in the last year, for Pro members

From SEC EDGAR, as filed. Each opens the filing on the SEC's site.

Why ODTX isn't scored

The Quality Score reads US-listed stocks worth $50M or more that trade at $1 or more and 300,000 shares or $10M a day. ODTX trades about 286,000 shares a day. A stock that clears every mark is scored from the next weekly rebuild.

Straight AnswersStraight Answers

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

Every US stock, ranked live.

Insider and Congress trades, the chart, and the financials, in one score.

See every stock ranked

See it live, free until Thursday morning. No account. No card. Then keep going with a free account.

The price on this page is delayed at least 15 minutes.

Breakaway publishes impersonal securities research and analytical tools: one formula, the same score for everyone. It is not personalized investment advice, and nothing here is a recommendation to buy or sell any security.

Market data from a licensed vendor. The age of every quote is shown on the page.

This browser is too old to show this page right. Update it, or open this page in Safari or Chrome.